Breast cancer molecular subtypes, including luminal A, luminal B, HER2-enriched, and basal-like (Fig. 2), were suggested firstly by Perou et al. [62] as an approach to explain the differences in therapeutic responses and patient outcomes beyond what could be achieved alone by tumour nuclear grade and size. Here, ERBB2 is linked to neoplasm.